Bone anabolic versus bone anticatabolic treatment of postmenopausal osteoporosis (Q37788771)

23 August 2017

title

Bone anabolic versus bone anticatabolic treatment of postmenopausal osteoporosis (English)

1 reference

23 August 2017

0 references

Thomas Georgoulas

2

1 reference

23 August 2017

George P. Lyritis

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20840284

13 July 2024

Christos P. Zafeiris

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20840284

13 July 2024

language of work or name

English

0 references

publication date

1 September 2010

1 reference

full work available at URL

23 August 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1749-6632.2010.05666.x

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

https://nyaspubs.onlinelibrary.wiley.com/doi/pdf/10.1111/j.1749-6632.2010.05666.x

13 July 2024

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Annals of the New York Academy of Sciences

13 July 2024

published in

1 reference

23 August 2017

volume

1205

1 reference

23 August 2017

page(s)

277-283

1 reference

Bone strength and its determinants

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05666.X

Bone modeling and remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05666.X

The cellular and clinical parameters of anabolic therapy for osteoporosis

21 January 2018

1

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Birth and Death of Bone Cells: Basic Regulatory Mechanisms and Implications for the Pathogenesis and Treatment of Osteoporosis 1

13 July 2024

2

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Bone remodeling rate and remodeling balance are not co-regulated in adulthood: implications for the use of activation frequency as an index of remodeling rate

13 July 2024

3

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

13 July 2024

4

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Rebalancing bone turnover in favour of formation with strontium ranelate: implications for bone strength.

13 July 2024

5

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Bone quality--the material and structural basis of bone strength and fragility

13 July 2024

6

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Bone remodelling: its local regulation and the emergence of bone fragility.

13 July 2024

7

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Proteolysis of latent transforming growth factor-beta (TGF-beta )-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix.

13 July 2024

8

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass

13 July 2024

9

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Leptin regulation of bone resorption by the sympathetic nervous system and CART

13 July 2024

10

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Role of stromal cells in osteoclast differentiation in bone marrow.

13 July 2024

13

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Multiple roles of M-CSF in human osteoclastogenesis

13 July 2024

14

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

RANK/RANKL: regulators of immune responses and bone physiology

13 July 2024

15

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Functions of RANKL/RANK/OPG in bone modeling and remodeling

13 July 2024

18

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Direct and indirect estrogen actions on osteoblasts and osteoclasts

13 July 2024

20

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

The mechanisms of estrogen regulation of bone resorption

13 July 2024

21

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength

13 July 2024

22

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Sex steroids and the construction and conservation of the adult skeleton

13 July 2024

23

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Estradiol rapidly inhibits osteoclastogenesis and RANKL expression in bone marrow cultures in postmenopausal women: a pilot study

13 July 2024

24

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Understanding the mechanisms of senile osteoporosis: new facts for a major geriatric syndrome

13 July 2024

26

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

13 July 2024

29

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

13 July 2024

30

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

13 July 2024

31

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Transmission of human herpesvirus 8 by blood transfusion

13 July 2024

32

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

13 July 2024

33

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Teriparatide: a review of its use in osteoporosis.

13 July 2024

34

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

The effects of PTH (1-34) on bone structure and strength in ovariectomized monkeys

13 July 2024

35

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats

13 July 2024

36

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

13 July 2024

37

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Monitoring pharmacological therapy for osteoporosis

13 July 2024

38

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture

13 July 2024

39

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

13 July 2024

40

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

13 July 2024

41

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective

13 July 2024

42

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

The relative merits of anabolics versus anti-resorptive compounds: where our targets should be, and whether we are addressing them

13 July 2024

43

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Super-osteons (remodeling clusters) in the cortex of the femoral shaft: influence of age and gender.

13 July 2024

44

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Treatment of osteoporosis with parathyroid peptide (hPTH 1–34) and oestrogen: increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone

13 July 2024

45

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure

13 July 2024

46

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study

13 July 2024

47

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women

13 July 2024

49

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys

13 July 2024

50

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

13 July 2024

51

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

13 July 2024

52

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate

13 July 2024

53

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Strontium ranelate: short- and long-term benefits for post-menopausal women with osteoporosis

13 July 2024

55

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial

13 July 2024

56

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05666.X

13 July 2024

Identifiers

1 reference

23 August 2017

1 reference